GLP-1 vs Tirzepatide vs Retatrutide: Next-Gen Weight Loss Medications Compared

Medical disclaimer: The information in this article is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. Lab results and reference ranges vary by individual, lab, age, sex, and health history. Always consult a qualified healthcare provider before making any decisions about your health, medications, supplements, or lab testing. LabHealthCharts is a data visualization tool — it organizes and displays your lab data, it does not interpret your results or provide medical guidance.

From one hormone to three: how weight loss injections evolved

Weight loss pharmacology changed dramatically when researchers realized the gut secretes not one but several hormones that coordinate hunger, insulin release, and energy balance. GLP-1 medications like semaglutide were the first to reach wide clinical use, and they produced weight loss numbers that had not been seen in drug trials before. Then tirzepatide added a second receptor to the target list and pushed those numbers higher. Now retatrutide — still in clinical trials as of 2025 — adds a third receptor and is producing results that are rewriting what pharmacological weight loss is expected to look like.

If you are weighing options with a clinician, trying to understand what your current medication is actually doing in your body, or wondering how to monitor your health while on one of these drugs, this comparison covers what matters: mechanisms in plain terms, what the trials showed, what the side effect profiles look like, and which labs you should have in front of you at every follow-up visit.

How each drug works: single, dual, and triple receptor agonism

GLP-1 receptor agonists — the foundation

GLP-1 stands for glucagon-like peptide-1, a hormone your small intestine releases after you eat. In plain terms, it tells the pancreas to release insulin in response to a meal, slows the rate at which food leaves the stomach (so you feel full longer), and signals the brain's appetite centers to reduce hunger. GLP-1 receptor agonists are synthetic molecules that mimic this hormone but last far longer in the body than the natural version does.

Semaglutide — sold as Ozempic for type 2 diabetes and Wegovy for obesity — is the most widely prescribed GLP-1 medication globally. It is administered as a once-weekly subcutaneous injection. In the STEP 1 trial, adults with obesity and without diabetes who took semaglutide 2.4 mg weekly lost a mean of approximately 14.9% of body weight over 68 weeks, compared with 2.4% on placebo. That result, published in The New England Journal of Medicine in 2021, established the benchmark against which newer agents are now compared.

A single lab draw while on semaglutide gives you a snapshot. What a series of draws three months apart reveals — trends in HbA1c, fasting glucose, triglycerides, and liver enzymes — tells a much more informative story about how your metabolism is responding.

Tirzepatide — adding GIP to the mix

Tirzepatide (brand names Mounjaro for diabetes, Zepbound for obesity) targets two receptors: GLP-1 and GIP. GIP stands for glucose-dependent insulinotropic polypeptide, another gut hormone that works alongside GLP-1 to stimulate insulin secretion. On its own, GIP has limited effects on weight. But when combined with GLP-1 agonism, the two pathways appear to work synergistically — particularly in reducing body fat while preserving lean mass, an important distinction.

The SURMOUNT-1 trial, published in The New England Journal of Medicine in 2022, found that adults with obesity taking the highest dose of tirzepatide (15 mg weekly) lost a mean of approximately 20.9% of body weight over 72 weeks. At 5 mg and 10 mg doses, mean weight loss was approximately 15.0% and 19.5% respectively. Each dose outperformed the semaglutide benchmark from STEP 1, with the gap widening at higher doses.

Tirzepatide received FDA approval for type 2 diabetes in 2022 and for chronic weight management in 2023. It is a once-weekly injection, making its practical schedule identical to semaglutide — though the two drugs are titrated on different schedules and are not interchangeable.

Retatrutide — adding glucagon as a third target

Retatrutide is a triple agonist that targets GLP-1, GIP, and the glucagon receptor simultaneously. Glucagon is the hormone that raises blood sugar by signaling the liver to release stored glucose — the opposite job from insulin. At first glance, activating a glucagon receptor sounds counterproductive for weight loss. But at the lower, controlled doses used in this drug, glucagon receptor agonism increases energy expenditure: the liver burns more fat and the resting metabolic rate rises. The net effect in the combination appears to amplify fat loss beyond what GLP-1 plus GIP achieves alone.

Retatrutide is still investigational. As of 2025 it has not received FDA approval for any indication. A phase 2 dose-ranging trial published in The New England Journal of Medicine in 2023 reported that participants taking the highest dose (12 mg once weekly) lost a mean of approximately 24.2% of body weight over 48 weeks. Phase 3 trials are ongoing, and no approval timeline is confirmed. Any patient interest in this drug should currently be framed as a question about research access, not a clinical option.

Efficacy comparison: what the trials actually showed

Reading trial results across different drugs requires caution. No head-to-head phase 3 trial comparing all three directly has been published. Trial populations, follow-up durations, dosing protocols, and definitions of endpoints differ. The numbers below represent the best available evidence from primary sources and should be treated as ranges, not precise predictions for any individual.

Beyond scale weight, all three drug classes consistently improve HbA1c (a 3-month average of blood sugar levels), fasting glucose, triglycerides, and, to varying degrees, blood pressure. Tirzepatide has shown particularly strong lipid effects in some analyses. The cardiovascular outcomes trial for semaglutide 2.4 mg (SELECT) found a 20% relative risk reduction in major adverse cardiovascular events in adults with established cardiovascular disease and obesity but without diabetes — a finding published in The New England Journal of Medicine in 2023 that moved these drugs from weight-loss tools to cardiovascular risk-reduction medications in many clinicians' thinking. Comparable cardiovascular outcomes data for tirzepatide are in development (SURMOUNT-MMO trial), and retatrutide cardiovascular data do not yet exist.

Side effects and tolerability: what to expect and what to watch for

The GI profile is a class effect

Nausea is the most common side effect across all three drug classes. It is most pronounced during the dose escalation phase — the weeks when the dose is being stepped up gradually — and typically improves once a stable dose is reached. Vomiting, constipation, and diarrhea are also frequently reported. For most people these effects are manageable, but for a minority they are severe enough to require dose reduction or discontinuation.

A practical strategy many clinicians use is slow titration: starting at the lowest dose and spending more time at each step than the minimum schedule requires. The pharmacology that slows stomach emptying — which contributes to both satiety and nausea — appears to be dose-dependent, so moving up gradually gives the gut time to adapt.

Serious risks: rare but important to know

All GLP-1 receptor agonists carry a boxed warning about thyroid C-cell tumors (medullary thyroid carcinoma, or MTC) based on rodent studies. Whether this translates to human risk remains debated; a large pharmacoepidemiological study published in BMJ found an association between GLP-1 use and thyroid cancer risk, while other analyses have not replicated it with consistent effect sizes. The FDA contraindication for anyone with a personal or family history of MTC or multiple endocrine neoplasia type 2 (MEN2) stands regardless. Pancreatitis has also been raised as a concern. The causal evidence is mixed, but clinicians typically advise patients to report any severe or persistent abdominal pain and may order amylase or lipase levels if symptoms arise.

For retatrutide specifically, the phase 2 trial reported a dose-dependent increase in resting heart rate — a signal the glucagon receptor component may be driving. This was roughly consistent with effects seen with other glucagon-containing molecules in earlier research. Whether this translates to clinical significance at phase 3 doses will require larger safety datasets. People with cardiac arrhythmia history or elevated resting heart rate at baseline should raise this explicitly with their prescriber before any triple agonist becomes available.

Muscle mass and body composition: a nuance the scale misses

Rapid weight loss from any cause includes some lean mass loss alongside fat loss. Early analyses of tirzepatide suggest a more favorable fat-to-lean ratio compared to semaglutide, potentially due to GIP receptor signaling influencing adipose tissue directly. Retatrutide's glucagon component is thought to drive preferential visceral fat mobilization. Neither of these differences is definitively established in long-term head-to-head data yet, but they may become relevant when interpreting body composition changes alongside lab trends. Creatinine levels, for example, can fall modestly with lean mass loss — which can make eGFR appear artificially improved. That is worth knowing when reading your kidney function results over time.

Practical considerations: dosing, availability, and access

Both semaglutide and tirzepatide are once-weekly subcutaneous injections administered with a pre-filled auto-injector pen. Both are titrated upward over several weeks or months to a target maintenance dose. The specific titration schedules differ between products and are set by the prescribing clinician based on the approved label — do not assume the schedule for one drug applies to the other.

As of 2025, semaglutide (Wegovy) is FDA-approved for chronic weight management in adults with a BMI of 30 or above, or 27 or above with at least one weight-related comorbidity. Tirzepatide (Zepbound) carries nearly identical approval criteria. Both require a prescription. Insurance coverage for obesity pharmacotherapy varies significantly by plan and continues to evolve as payers respond to cardiovascular outcomes data; a prescriber's office or a specialty pharmacist is the most accurate source for current coverage information.

Retatrutide is not available outside of clinical trials as of this writing. If phase 3 results match or exceed the phase 2 signal, FDA review would be a logical next step — but regulatory timelines are not predictable. Oral formulations of semaglutide exist (Rybelsus, approved for type 2 diabetes), and oral obesity-dose GLP-1 medications are in development, which may eventually change the injection-only landscape.

Questions to bring to a clinician — not a checklist of who should take which drug

The right medication depends on individual health history, comorbidities, insurance coverage, prior treatment response, and personal preference — none of which a general article can assess. What an informed patient can do is walk into the conversation with the right questions.

Ask your clinician: whether you have contraindications to GLP-1 receptor agonism (personal or family history of MTC or MEN2, history of pancreatitis); which baseline labs should be established before starting; what a reasonable retesting schedule looks like at 3 and 6 months; which metabolic markers they plan to use as success or safety indicators; and whether cardiovascular risk is a factor in choosing between agents. If you are being considered for a clinical trial for retatrutide or another investigational agent, ask specifically about what additional monitoring is required.

For people already on one of these medications, a useful second question set covers: what the trend in their labs has looked like since starting, whether any values require a dose adjustment or investigation, and how long treatment is expected to continue. Weight regain after discontinuation is well-documented with both semaglutide and tirzepatide — a conversation about long-term strategy is relevant early, not just if results plateau.

The labs that matter most on any of these medications

Understanding what to monitor — and why each marker matters — makes follow-up appointments more productive. Here is a plain-language breakdown of the markers most clinicians track, and what direction you might expect them to move on effective therapy.

HbA1c and fasting glucose

HbA1c (hemoglobin A1c) is a 3-month average of your blood sugar levels, expressed as a percentage. Normal is typically below 5.7%; prediabetes is 5.7–6.4%; type 2 diabetes is 6.5% and above. For people with diabetes or prediabetes, this is the primary marker of medication effect. For people without diabetes, fasting glucose is more informative visit-to-visit, since their HbA1c may already be in the normal range and shifts can be subtle. All three drug classes reliably improve both markers in people with metabolic dysfunction, with tirzepatide showing particularly strong HbA1c reductions in T2D trials.

Lipid panel: triglycerides, LDL, and HDL

Triglycerides typically fall early and substantially on GLP-1 medications — often the first lipid change visible on a 3-month draw. LDL cholesterol changes are more variable: modest decreases are common, but the magnitude depends on weight loss, diet changes, and baseline levels. HDL often rises modestly. These shifts matter holistically because they sit alongside blood pressure changes and inflammatory markers as part of the cardiovascular risk picture, not as isolated numbers. If you want to see how your lipid panel is trending relative to, say, your fasting glucose and ALT on the same timeline, that is exactly the kind of multi-marker view that longitudinal tracking enables.

Liver enzymes: ALT and AST

ALT (alanine aminotransferase) and AST (aspartate aminotransferase) are enzymes that rise when liver cells are stressed or damaged. Metabolic dysfunction-associated steatotic liver disease (MASLD, previously called NAFLD) is common in people with obesity and insulin resistance — and GLP-1 medications have shown meaningful reductions in liver fat in imaging studies. ALT often falls on these drugs as liver health improves, making it a useful indirect marker of hepatic response. A transient mild elevation during the first weeks of therapy has been reported in some patients and is worth flagging to a clinician if it persists.

Kidney function: eGFR and creatinine

eGFR (estimated glomerular filtration rate) is an estimate of how well your kidneys are filtering. It is calculated from your creatinine level, age, and sex. On these medications, eGFR can appear to improve — but some of that apparent improvement reflects the drop in creatinine that comes with lean mass loss, not necessarily better kidney function. Watching both creatinine and eGFR together over time, alongside weight trajectory, gives a cleaner read than either alone.

Amylase and lipase — only when symptomatic

Amylase and lipase are pancreatic enzymes that rise acutely in pancreatitis. Routine monitoring of these is not standard in the absence of symptoms. However, if a patient on any GLP-1 class medication develops severe, persistent upper abdominal pain — particularly pain that radiates to the back — a clinician will typically order these urgently. Knowing what the test is and why it might be ordered gives patients context to seek timely care.

Future directions: oral agents and the competitive pipeline

Oral semaglutide at obesity-range doses is in phase 3 trials and may significantly change adherence dynamics if approved — subcutaneous injections are well-tolerated by most users but are a barrier for some. Several other triple and even quad-agonist molecules are in early development. The broader trend in metabolic pharmacology is toward molecules that do more than suppress appetite: they shift energy expenditure, remodel adipose tissue, and may eventually be paired with muscle-preservation agents.

For the lab tracking question, this trajectory matters because newer mechanisms may produce different signals in standard panels. A triple agonist with stronger glucagon activity may produce more pronounced changes in fasting glucose, liver enzymes, or heart rate markers than a pure GLP-1 agent. Keeping a continuous lab history — rather than isolated annual snapshots — positions patients and clinicians to detect those differences early and respond to them.

Why tracking your labs over time matters more than any single result on these medications

A single lab result while on a GLP-1 medication tells you where you are on one day. What your clinician actually needs — and what you need to make informed decisions — is the direction and rate of change across multiple draws. HbA1c trending from 7.2% to 6.4% to 5.9% over 12 months on tirzepatide tells a completely different story than a one-time result of 6.4% with no history. The same applies to ALT (is the liver responding?), triglycerides (are cardiovascular risk markers improving?), and eGFR (is the lean-mass-adjusted kidney function picture stable?). Trend is the signal; a single point is noise.

This is exactly where LabHealthCharts is built to help. You upload your lab PDFs — from Quest, LabCorp, or most standard lab formats — and the app uses AI-assisted extraction to pull your biomarker values into structured longitudinal charts. Instead of comparing last quarter's paper printout to the one from six months ago while sitting in a waiting room, you see your HbA1c, fasting glucose, lipid panel, ALT, and eGFR all plotted on a timeline in one account. Over 100 biomarkers are tracked, and your history stays unified across providers and visits.

For anyone on a GLP-1 medication, tirzepatide, or monitoring a clinical trial protocol, the recommended retesting cadence — typically 3 months, 6 months, and then annually once stable — generates exactly the kind of serial data that becomes meaningful when visualized together. You can upload your labs and chart them over time at app.labhealthcharts.com; the first report is free and unlimited membership is $99 per year.

LabHealthCharts organizes and visualizes your data — it does not interpret your results or provide medical guidance. Interpretation of what the trends mean for your treatment stays with your clinician. What the app changes is that you show up to that conversation with a chart in hand, not a stack of PDFs and a memory of which number looked different last time.

For more on specific markers covered in this article, see the LabHealthCharts biomarker research library, including detailed explainers on cardiovascular markers like ApoB vs LDL — a marker whose interpretation is especially relevant for people managing metabolic risk on these medications.

Key Takeaways

GLP-1 medications, tirzepatide, and retatrutide represent three generations of the same core idea — mimicking gut hormones to reduce hunger and improve metabolic function — with each generation adding receptor targets that appear to amplify efficacy:

Semaglutide (GLP-1 only) produced approximately 14–15% mean weight loss in major trials and is the only agent in this class with published cardiovascular outcomes data showing benefit. It is FDA-approved for obesity.

Tirzepatide (GLP-1 + GIP) produced approximately 15–21% mean weight loss at various doses in SURMOUNT-1 and is FDA-approved for obesity. Its dual mechanism appears to produce particularly strong metabolic effects on lipids and HbA1c.

Retatrutide (GLP-1 + GIP + glucagon) is investigational. Phase 2 data showed approximately 24% mean weight loss at the highest dose over 48 weeks — but it has not been FDA-approved, longer-term safety data are limited, and it is not available outside clinical trials.

All three share a GI side effect profile dominated by nausea during titration, carry contraindications for people with MTC or MEN2 history, and require a similar panel of labs for baseline and follow-up monitoring: HbA1c, fasting glucose, lipid panel, ALT/AST, and kidney function.

No head-to-head phase 3 trial comparing all three directly has been published. Comparing efficacy across separate trials requires caution — populations, duration, and dosing schedules differ.

The metabolic story these drugs tell shows up most clearly in serial lab data, not single draws. If you are on one of these medications, ask your clinician about a retesting schedule at 3 and 6 months — and track those results together over time so the trend is visible, not buried in separate PDFs.